{"title":"从全国心律失常队列中寻找基于ED的心脏肿瘤途径","authors":"Yalcin Golcuk","doi":"10.1002/joa3.70167","DOIUrl":null,"url":null,"abstract":"<p>The landmark study by Kobayashi and Kusano [<span>1</span>] provides invaluable insights into arrhythmia patterns among cancer patients using Japan's nationwide JROAD-DPC database. Despite the rising incidence of cardiovascular complications in oncology patients, few large-scale studies have examined arrhythmia profiles across cancer subtypes and treatment trajectories in real-world emergency settings. As emergency physicians (EPs) managing acute cardio-oncologic complications, we commend this study and wish to highlight three findings with critical implications for emergency care, along with opportunities to strengthen clinical translation.</p><p>The significantly higher rate of emergency admissions among cancer patients with arrhythmias (58.9% vs. 57.6% in non-cancer patients; <i>p</i> < 0.05) underscores a growing challenge for emergency departments (EDs). This finding aligns with global trends showing increasing cardiovascular emergencies related to malignancy due to aging populations and the widespread use of cardiotoxic therapies [<span>2</span>]. However, the underlying factors contributing to these admissions—whether related to arrhythmia severity, cancer progression, or gaps in outpatient care—remain insufficiently explored. Clarifying these drivers could enable the implementation of targeted interventions such as rapid-access cardio-oncology clinics or ED-based clinical triggers, including recurrent arrhythmia or recent chemotherapy exposure, for early cardiology consultation.</p><p>The predominance of atrial fibrillation or flutter (AF/AFL) among cancer-associated arrhythmias, comprising 70.6% of cases, has direct implications for acute management in the ED [<span>3</span>]. While the authors report lower anticoagulant use among cancer patients, EPs frequently face complex therapeutic dilemmas. Rhythm control may be constrained by QT-prolonging chemotherapies, and anticoagulation decisions must be cautiously balanced against risks of bleeding, especially in the context of thrombocytopenia or mucosal tumors. ED-specific algorithms would benefit from integrating oncology-informed variables such as current drug profiles, platelet counts, and malignancy characteristics to individualize AF management.</p><p>The observed frequencies of pneumonia (7.41%) and sepsis (2.26%) as clinical triggers for arrhythmia underscore the role of systemic inflammation in acute cardiac dysrhythmias. In the ED, febrile presentations in oncology patients often signal infection-related arrhythmogenic potential [<span>4</span>]. Embedding arrhythmia screening protocols, such as mandatory electrocardiograms for patients with febrile neutropenia, within sepsis bundles may support early detection of tachyarrhythmias and timely antimicrobial or hemodynamic intervention.</p><p>This study's use of nationwide claims data effectively captures broad epidemiologic trends; although coding limitations restrict the granularity of arrhythmia etiology and disease trajectory. Future prospective studies that correlate arrhythmia subtypes with cancer stage, treatment modality, and ED-centered outcomes such as return visits or time to cardiology consultation may yield actionable risk stratification models. Moreover, the absence of disposition-level data represents a missed opportunity to inform quality improvement efforts in emergency cardio-oncology workflows.</p><p>In conclusion, Kobayashi and Kusano's study compellingly validates the evolving role of the ED in cardio-oncology care. To operationalize these insights, we propose collaborative development of three core strategies: ED-specific risk scores for arrhythmias in cancer patients, standardized AF management pathways for patients with thrombocytopenia, and integrated infection-arrhythmia screening tools. We believe this is a critical juncture to embed cardio-oncology into ED frameworks, advancing from reactive stabilization toward anticipatory, coordinated care.</p><p><b>Yalcin Golcuk:</b> conceptualization, writing – original draft, writing – review and editing.</p><p>The author declares no conflicts of interest.</p><p>This article is linked to Kobayashi and Kusano's article. To view this article, visit https://doi.org/10.1002/joa3.70079.</p>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"41 4","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.70167","citationCount":"0","resultStr":"{\"title\":\"Toward ED Based Cardio Oncology Pathways From a Nationwide Arrhythmia Cohort\",\"authors\":\"Yalcin Golcuk\",\"doi\":\"10.1002/joa3.70167\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The landmark study by Kobayashi and Kusano [<span>1</span>] provides invaluable insights into arrhythmia patterns among cancer patients using Japan's nationwide JROAD-DPC database. Despite the rising incidence of cardiovascular complications in oncology patients, few large-scale studies have examined arrhythmia profiles across cancer subtypes and treatment trajectories in real-world emergency settings. As emergency physicians (EPs) managing acute cardio-oncologic complications, we commend this study and wish to highlight three findings with critical implications for emergency care, along with opportunities to strengthen clinical translation.</p><p>The significantly higher rate of emergency admissions among cancer patients with arrhythmias (58.9% vs. 57.6% in non-cancer patients; <i>p</i> < 0.05) underscores a growing challenge for emergency departments (EDs). This finding aligns with global trends showing increasing cardiovascular emergencies related to malignancy due to aging populations and the widespread use of cardiotoxic therapies [<span>2</span>]. However, the underlying factors contributing to these admissions—whether related to arrhythmia severity, cancer progression, or gaps in outpatient care—remain insufficiently explored. Clarifying these drivers could enable the implementation of targeted interventions such as rapid-access cardio-oncology clinics or ED-based clinical triggers, including recurrent arrhythmia or recent chemotherapy exposure, for early cardiology consultation.</p><p>The predominance of atrial fibrillation or flutter (AF/AFL) among cancer-associated arrhythmias, comprising 70.6% of cases, has direct implications for acute management in the ED [<span>3</span>]. While the authors report lower anticoagulant use among cancer patients, EPs frequently face complex therapeutic dilemmas. Rhythm control may be constrained by QT-prolonging chemotherapies, and anticoagulation decisions must be cautiously balanced against risks of bleeding, especially in the context of thrombocytopenia or mucosal tumors. ED-specific algorithms would benefit from integrating oncology-informed variables such as current drug profiles, platelet counts, and malignancy characteristics to individualize AF management.</p><p>The observed frequencies of pneumonia (7.41%) and sepsis (2.26%) as clinical triggers for arrhythmia underscore the role of systemic inflammation in acute cardiac dysrhythmias. In the ED, febrile presentations in oncology patients often signal infection-related arrhythmogenic potential [<span>4</span>]. Embedding arrhythmia screening protocols, such as mandatory electrocardiograms for patients with febrile neutropenia, within sepsis bundles may support early detection of tachyarrhythmias and timely antimicrobial or hemodynamic intervention.</p><p>This study's use of nationwide claims data effectively captures broad epidemiologic trends; although coding limitations restrict the granularity of arrhythmia etiology and disease trajectory. Future prospective studies that correlate arrhythmia subtypes with cancer stage, treatment modality, and ED-centered outcomes such as return visits or time to cardiology consultation may yield actionable risk stratification models. Moreover, the absence of disposition-level data represents a missed opportunity to inform quality improvement efforts in emergency cardio-oncology workflows.</p><p>In conclusion, Kobayashi and Kusano's study compellingly validates the evolving role of the ED in cardio-oncology care. To operationalize these insights, we propose collaborative development of three core strategies: ED-specific risk scores for arrhythmias in cancer patients, standardized AF management pathways for patients with thrombocytopenia, and integrated infection-arrhythmia screening tools. We believe this is a critical juncture to embed cardio-oncology into ED frameworks, advancing from reactive stabilization toward anticipatory, coordinated care.</p><p><b>Yalcin Golcuk:</b> conceptualization, writing – original draft, writing – review and editing.</p><p>The author declares no conflicts of interest.</p><p>This article is linked to Kobayashi and Kusano's article. To view this article, visit https://doi.org/10.1002/joa3.70079.</p>\",\"PeriodicalId\":15174,\"journal\":{\"name\":\"Journal of Arrhythmia\",\"volume\":\"41 4\",\"pages\":\"\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-08-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.70167\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Arrhythmia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/joa3.70167\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Arrhythmia","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/joa3.70167","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
Kobayashi和Kusano的这项具有里程碑意义的研究利用日本全国性的JROAD-DPC数据库为癌症患者的心律失常模式提供了宝贵的见解。尽管肿瘤患者心血管并发症的发生率不断上升,但很少有大规模的研究检查了不同癌症亚型的心律失常概况和现实世界急诊环境中的治疗轨迹。作为急诊医生(EPs)管理急性心脏肿瘤并发症,我们赞扬这项研究,并希望强调三个对急诊护理具有重要意义的发现,以及加强临床翻译的机会。癌症患者合并心律失常的急诊入院率显著高于非癌症患者(58.9% vs. 57.6%);p < 0.05)凸显了急诊科(ed)面临的日益严峻的挑战。这一发现与全球趋势一致,即由于人口老龄化和心脏毒性疗法的广泛使用,与恶性肿瘤相关的心血管紧急情况不断增加[10]。然而,导致这些住院的潜在因素——是否与心律失常严重程度、癌症进展或门诊护理的空白有关——仍然没有得到充分的探讨。澄清这些驱动因素有助于实施有针对性的干预措施,如快速进入心脏肿瘤学诊所或基于ed的临床触发因素,包括复发性心律失常或近期化疗暴露,用于早期心脏病学咨询。心房颤动或扑动(AF/AFL)在癌症相关心律失常中的优势,占70.6%的病例,对ED bbb的急性管理有直接的影响。虽然作者报告了癌症患者抗凝血药的使用较低,但EPs经常面临复杂的治疗困境。节律控制可能受到延长qt化疗的限制,抗凝决定必须谨慎地与出血风险相平衡,特别是在血小板减少症或粘膜肿瘤的情况下。ed特异性算法将受益于整合肿瘤学信息变量,如当前药物谱、血小板计数和恶性肿瘤特征,以个性化房颤管理。观察到的肺炎(7.41%)和败血症(2.26%)作为心律失常的临床触发因素的频率强调了全身性炎症在急性心律失常中的作用。在急诊科,肿瘤患者的发热表现通常是感染相关的致心律失常的潜在信号。在脓毒症包中嵌入心律失常筛查方案,如发热性中性粒细胞减少症患者的强制性心电图,可能有助于早期发现心律失常并及时进行抗菌或血流动力学干预。这项研究使用了全国索赔数据,有效地捕捉了广泛的流行趋势;尽管编码的局限性限制了心律失常病因和疾病轨迹的粒度。未来的前瞻性研究将心律失常亚型与癌症分期、治疗方式和以ed为中心的结果(如复诊或心脏病学咨询时间)联系起来,可能产生可操作的风险分层模型。此外,性格水平数据的缺乏意味着错过了为急诊心脏肿瘤学工作流程的质量改进工作提供信息的机会。总之,Kobayashi和Kusano的研究令人信服地证实了ED在心脏肿瘤治疗中的作用。为了实现这些见解,我们建议合作开发三个核心策略:癌症患者心律失常的ed特异性风险评分,血小板减少患者的标准化房颤管理途径,以及综合感染-心律失常筛查工具。我们相信这是将心脏肿瘤学纳入ED框架的关键时刻,从反应性稳定向预期性协调护理迈进。Yalcin Golcuk:构思,写作-原稿,写作-审查和编辑。作者声明无利益冲突。这篇文章链接到小林和草野的文章。要查看本文,请访问https://doi.org/10.1002/joa3.70079。
Toward ED Based Cardio Oncology Pathways From a Nationwide Arrhythmia Cohort
The landmark study by Kobayashi and Kusano [1] provides invaluable insights into arrhythmia patterns among cancer patients using Japan's nationwide JROAD-DPC database. Despite the rising incidence of cardiovascular complications in oncology patients, few large-scale studies have examined arrhythmia profiles across cancer subtypes and treatment trajectories in real-world emergency settings. As emergency physicians (EPs) managing acute cardio-oncologic complications, we commend this study and wish to highlight three findings with critical implications for emergency care, along with opportunities to strengthen clinical translation.
The significantly higher rate of emergency admissions among cancer patients with arrhythmias (58.9% vs. 57.6% in non-cancer patients; p < 0.05) underscores a growing challenge for emergency departments (EDs). This finding aligns with global trends showing increasing cardiovascular emergencies related to malignancy due to aging populations and the widespread use of cardiotoxic therapies [2]. However, the underlying factors contributing to these admissions—whether related to arrhythmia severity, cancer progression, or gaps in outpatient care—remain insufficiently explored. Clarifying these drivers could enable the implementation of targeted interventions such as rapid-access cardio-oncology clinics or ED-based clinical triggers, including recurrent arrhythmia or recent chemotherapy exposure, for early cardiology consultation.
The predominance of atrial fibrillation or flutter (AF/AFL) among cancer-associated arrhythmias, comprising 70.6% of cases, has direct implications for acute management in the ED [3]. While the authors report lower anticoagulant use among cancer patients, EPs frequently face complex therapeutic dilemmas. Rhythm control may be constrained by QT-prolonging chemotherapies, and anticoagulation decisions must be cautiously balanced against risks of bleeding, especially in the context of thrombocytopenia or mucosal tumors. ED-specific algorithms would benefit from integrating oncology-informed variables such as current drug profiles, platelet counts, and malignancy characteristics to individualize AF management.
The observed frequencies of pneumonia (7.41%) and sepsis (2.26%) as clinical triggers for arrhythmia underscore the role of systemic inflammation in acute cardiac dysrhythmias. In the ED, febrile presentations in oncology patients often signal infection-related arrhythmogenic potential [4]. Embedding arrhythmia screening protocols, such as mandatory electrocardiograms for patients with febrile neutropenia, within sepsis bundles may support early detection of tachyarrhythmias and timely antimicrobial or hemodynamic intervention.
This study's use of nationwide claims data effectively captures broad epidemiologic trends; although coding limitations restrict the granularity of arrhythmia etiology and disease trajectory. Future prospective studies that correlate arrhythmia subtypes with cancer stage, treatment modality, and ED-centered outcomes such as return visits or time to cardiology consultation may yield actionable risk stratification models. Moreover, the absence of disposition-level data represents a missed opportunity to inform quality improvement efforts in emergency cardio-oncology workflows.
In conclusion, Kobayashi and Kusano's study compellingly validates the evolving role of the ED in cardio-oncology care. To operationalize these insights, we propose collaborative development of three core strategies: ED-specific risk scores for arrhythmias in cancer patients, standardized AF management pathways for patients with thrombocytopenia, and integrated infection-arrhythmia screening tools. We believe this is a critical juncture to embed cardio-oncology into ED frameworks, advancing from reactive stabilization toward anticipatory, coordinated care.
Yalcin Golcuk: conceptualization, writing – original draft, writing – review and editing.
The author declares no conflicts of interest.
This article is linked to Kobayashi and Kusano's article. To view this article, visit https://doi.org/10.1002/joa3.70079.